Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin plus Paclitaxel in Advanced Non-Squamous NSCLC
NCT02826161Phase 3Terminated
- Sponsor
- Sumitomo Pharma America
- Start
- Nov 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of napabucasin in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Sumitomo Pharma America. Started Nov 2016; status: terminated.
02
Drugs
napabucasin
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT02826161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02826161.